Carvolix

Carvolix EPS

The Earnings per Share (EPS) of Carvolix (CVX.PA) as of Nov 8, 2026 is -0.63 EUR. In the previous year, Earnings per Share (EPS) was -0.37 EUR — a change of 69.46% (lower).

EPS

-0.63EUR

YoY

69.46%

Last updated:

Earnings per Share (EPS) of Carvolix is 2025 -0.63 EUR. Earnings per Share (EPS) of Carvolix was 2024 -0.37 EUR. It decreases by 69.46% lower compared to the previous year.

The Carvolix EPS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EPS
Date
EPS
Jan 1, 2022
-0.77 EUR
Jan 1, 2023
-0.51 EUR
Jan 1, 2024
-0.37 EUR
Jan 1, 2025
-0.63 EUR
Jan 1, 2026 (e)
-0.44 EUR
Jan 1, 2027 (e)
-0.50 EUR
Jan 1, 2028 (e)
-0.30 EUR
Jan 1, 2029 (e)
0.15 EUR
The Carvolix EPS history
YEAREPSYoY
est0.15EUR-150.50%
est-0.30EUR-38.49%
est-0.50EUR+12.83%
est-0.44EUR-30.89%
-0.63EUR+69.46%
-0.37EUR-25.98%
-0.51EUR-34.18%
-0.77EUR-3.54%
-0.80EUR-18.81%
-0.98EUR+10.03%
-0.89EUR+24.18%
-0.72EUR+49.94%
-0.48EUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Carvolix Stock analysis

What does Carvolix do? Affluent Medical SA develops minimally invasive prostheses that mimic human anatomy and restore native physiology for cardiovascular and urological therapies. The company offers products including Kalios, Epygon, and Artus, targeting heart disease and urinary incontinence treatments. These solutions utilize transcatheter and flow control technologies with optimized, biocompatible components designed for minimally invasive implant procedures. The company's products are sold to healthcare providers and medical institutions seeking advanced solutions for critical conditions. Affluent Medical SA focuses on treating serious and widespread diseases through innovative implantable technologies that replicate natural bodily functions without extensive surgical intervention. With a workforce of 54 full-time employees based in Aix-En-Provence, Paca, the company delivers specialized medical devices that address unmet needs in cardiovascular and urological care. Its product portfolio targets high-value clinical segments where minimally invasive approaches improve patient outcomes and reduce recovery times. Carvolix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Carvolix stock

Earnings per Share (EPS) of Carvolix is -0.63 EUR in 2025.

Earnings per Share (EPS) of Carvolix changed from -0.37 EUR to -0.63 EUR, representing a 69.46% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Earnings per Share (EPS) Carvolix since 2006 – with annual values, charts, and detailed analysis.

Earnings per Share measures the portion of a company's profit allocated to each outstanding share. It is a key metric for assessing a company's profitability on a per-share basis.

EPS = Net Income / Shares Outstanding

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Carvolix

All Key Metrics — Carvolix